Literature DB >> 28812103

Re-expression of pro-fibrotic, embryonic preserved mediators in irradiated arterial vessels of the head and neck region.

Patrick Möbius1,2, Raimund H M Preidl3, Manuel Weber3, Kerstin Amann4, Friedrich W Neukam3, Falk Wehrhan3.   

Abstract

PURPOSE: Surgical treatment of head and neck malignancies frequently includes microvascular free tissue transfer. Preoperative radiotherapy increases postoperative fibrosis-related complications up to transplant loss. Fibrogenesis is associated with re-expression of embryonic preserved tissue developmental mediators: osteopontin (OPN), regulated by sex-determining region Y‑box 9 (Sox9), and homeobox A9 (HoxA9) play important roles in pathologic tissue remodeling and are upregulated in atherosclerotic vascular lesions; dickkopf-1 (DKK1) inhibits pro-fibrotic and atherogenic Wnt signaling. We evaluated the influence of irradiation on expression of these mediators in arteries of the head and neck region.
MATERIALS AND METHODS: DKK1, HoxA9, OPN, and Sox9 expression was examined immunohistochemically in 24 irradiated and 24 nonirradiated arteries of the lower head and neck region. The ratio of positive cells to total cell number (labeling index) in the investigated vessel walls was assessed semiquantitatively.
RESULTS: DKK1 expression was significantly decreased, whereas HoxA9, OPN, and Sox9 expression were significantly increased in irradiated compared to nonirradiated arterial vessels.
CONCLUSION: Preoperative radiotherapy induces re-expression of embryonic preserved mediators in arterial vessels and may thus contribute to enhanced activation of pro-fibrotic downstream signaling leading to media hypertrophy and intima degeneration comparable to fibrotic development steps in atherosclerosis. These histopathological changes may be promoted by HoxA9-, OPN-, and Sox9-related inflammation and vascular remodeling, supported by downregulation of anti-fibrotic DKK1. Future pharmaceutical strategies targeting these vessel alterations, e. g., bisphosphonates, might reduce postoperative complications in free tissue transfer.

Entities:  

Keywords:  Embryology; Immunohistochemistry; Inflammation; Radiotherapy; Vascular remodeling

Mesh:

Substances:

Year:  2017        PMID: 28812103     DOI: 10.1007/s00066-017-1192-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  50 in total

1.  Influence of irradiation and oncologic surgery on head and neck microsurgical reconstructions.

Authors:  Thomas Mücke; Andrea Rau; Jochen Weitz; Andreas Ljubic; Nils Rohleder; Klaus-Dietrich Wolff; David A Mitchell; Marco R Kesting
Journal:  Oral Oncol       Date:  2011-12-11       Impact factor: 5.337

2.  Vascularization of the area between free grafts and irradiated graft beds in the neck in rats.

Authors:  S Schultze-Mosgau; F Rödel; M Radespiel-Tröger; J Wörl; G G Grabenbauer; F W Neukam
Journal:  Br J Oral Maxillofac Surg       Date:  2002-02       Impact factor: 1.651

3.  Activation of stem-cell specific genes by HOXA9 and HOXA10 homeodomain proteins in CD34+ human cord blood cells.

Authors:  Christina M Ferrell; Sheri T Dorsam; Hideaki Ohta; R Keith Humphries; Mika Kakefuda Derynck; Chris Haqq; Corey Largman; H Jeffrey Lawrence
Journal:  Stem Cells       Date:  2005-05       Impact factor: 6.277

Review 4.  Radiation-induced fibrosis: mechanisms and implications for therapy.

Authors:  Jeffrey M Straub; Jacob New; Chase D Hamilton; Chris Lominska; Yelizaveta Shnayder; Sufi M Thomas
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-25       Impact factor: 4.553

5.  Transforming growth factor-beta receptor-II up-regulation during wound healing in previously irradiated graft beds in vivo.

Authors:  Stefan Schultze-Mosgau; Falk Wehrhan; Franz Rödel; Kerstin Amann; Martin Radespiel-Tröger; Gerhard G Grabenbauer
Journal:  Wound Repair Regen       Date:  2003 Jul-Aug       Impact factor: 3.617

6.  sFRP2 activates Wnt/β-catenin signaling in cardiac fibroblasts: differential roles in cell growth, energy metabolism, and extracellular matrix remodeling.

Authors:  Huey Lin; Mia Angeli; Kwang Jin Chung; Chukwuemeka Ejimadu; Angelica Rivera Rosa; Techung Lee
Journal:  Am J Physiol Cell Physiol       Date:  2016-09-07       Impact factor: 4.249

7.  Osteopontin is a novel marker of pancreatic ductal tissues and of undifferentiated pancreatic precursors in mice.

Authors:  Gamze Kilic; Junfeng Wang; Beatriz Sosa-Pineda
Journal:  Dev Dyn       Date:  2006-06       Impact factor: 3.780

8.  HOXA9 is Underexpressed in Cervical Cancer Cells and its Restoration Decreases Proliferation, Migration and Expression of Epithelial-to-Mesenchymal Transition Genes.

Authors:  Liliana Alvarado-Ruiz; Maria Guadalupe Martinez-Silva; Luis Alberto Torres-Reyes; Patricia Pina-Sanchez; Pablo Ortiz-Lazareno; Alejandro Bravo-Cuellar; Adriana Aguilar-Lemarroy; Luis Felipe Jave-Suarez
Journal:  Asian Pac J Cancer Prev       Date:  2016

9.  Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans.

Authors:  James Pritchett; Emma Harvey; Varinder Athwal; Andrew Berry; Cliff Rowe; Fiona Oakley; Anna Moles; Derek A Mann; Nicoletta Bobola; Andrew D Sharrocks; Brian J Thomson; Abed M Zaitoun; William L Irving; Indra N Guha; Neil A Hanley; Karen Piper Hanley
Journal:  Hepatology       Date:  2012-09       Impact factor: 17.425

10.  Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.

Authors:  Elena Arriazu; Xiaodong Ge; Tung-Ming Leung; Fernando Magdaleno; Aritz Lopategi; Yongke Lu; Naoto Kitamura; Raquel Urtasun; Neil Theise; Daniel J Antoine; Natalia Nieto
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

View more
  1 in total

1.  Long-term endothelial dysfunction in irradiated vessels: an immunohistochemical analysis.

Authors:  Raimund H M Preidl; Patrick Möbius; Manuel Weber; Kerstin Amann; Friedrich W Neukam; Marco Kesting; Carol-Immanuel Geppert; Falk Wehrhan
Journal:  Strahlenther Onkol       Date:  2018-10-15       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.